Learn
Research peptide guides, in plain English.
What the molecules actually do, how the testing works, and what to look for before you trust a label. No marketing voice, no brand-name comparisons, just the science the way researchers talk about it.
Free Tool
Reconstitution Calculator
Enter vial mg + water mL + dose, get the exact insulin-syringe units to draw. Plus the worked math.
Reference
Peptide Glossary
A-Z definitions for every term you encounter in a research peptide COA, product page, or article.
Latest from the literature
Updated dailyWhat researchers measured when using lower semaglutide doses for obesity
Most trials test the highest approved doses. This study asked what happens at lower doses in a real clinical setting, and the measurements surprised some researchers.
Source: Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study. (Scientific reports, Miertová Zuzana et al.)
A large study looks at GLP-1 peptides and eye disease risk
Does a widely used GLP-1 peptide raise or lower the risk of a vision-threatening eye condition? A large observational study tried to find out.
Source: Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study. (Ophthalmology, Cai Cindy X et al.)
Why oral GLP-1 peptides are so hard to absorb
Oral peptide drugs face a brutal gauntlet in the gut. A 2026 modelling study explains exactly where the losses happen and what researchers are doing about it.
Source: Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations. (Xenobiotica; the fate of foreign compounds in biological systems, Tiwari Ayushi et al.)
GLP-1 receptor agonists linked to lower knee replacement rates in large study
Could a class of metabolic peptides slow knee osteoarthritis enough to delay or prevent joint replacement surgery? A large real-world study crunched the numbers.
Source: Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. (Regional anesthesia and pain medicine, Carter Victoria et al.)
How blocking one enzyme may protect muscle during weight loss
GLP-1 receptor agonists drive meaningful weight loss, but research suggests they may also shrink muscle. A new mouse study explores whether blocking a single enzyme could change that outcome.
Source: 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss. (Proceedings of the National Academy of Sciences of the United States of America, Nalbandian Minas et al.)
How engineered vesicles delivered an anti-amyloid peptide to neurons
What happens when researchers attach a peptide designed to block amyloid clumping onto tiny natural-looking delivery vehicles and expose neurons to it?
Source: Engineered EV-mediated delivery of an anti-amyloid peptide provides neuroprotection in an in vitro Alzheimer's disease model. (International journal of pharmaceutics, Singh Varsha Birendra et al.)
How two metabolic receptors may quiet dopamine signals in the brain
Researchers found that activating gut-hormone receptors in a specific brain region reduced dopamine activity, raising new questions about how metabolic peptides interact with reward circuits.
Source: Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine. (ACS chemical neuroscience, Buchanan Anna Marie et al.)
GLP-1 peptides and eating disorders: what researchers are asking
GLP-1 receptor agonists are reshaping metabolic research, but a new spotlight article warns the field has not yet answered some important questions about eating behavior and psychological risk.
Source: Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities. (The International journal of eating disorders, Škudar Stjepan et al.)
How NMN may protect the liver from alcohol-related fat buildup
Researchers found that boosting NAD levels with NMN reversed a key liver protein deficiency and cut down fat accumulation in alcohol-fed mice. Here is what the data actually showed.
Source: Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice. (Communications biology, Cao Feiwei et al.)
GLP-1 peptides and survival after emergency stroke surgery
Could a peptide taken before a stroke change what happens afterward? A large retrospective analysis looked at exactly that question in patients who needed emergency clot-removal procedures.
Source: GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis. (Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, Rai Pranjal et al.)
How GLP-1 peptides may affect fat graft survival
Millions of people using GLP-1 peptides for weight loss are also candidates for fat grafting. A new review asks whether these two things can coexist.
Source: Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. (Aesthetic surgery journal, Chalhoub Xavier et al.)
What a large meta-analysis found about GLP-1 peptides and heart outcomes
Fifteen randomized trials, nearly 100,000 participants, and one clear signal: researchers found GLP-1-based therapies were tied to better cardiovascular outcomes as a class.
Source: The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. (Diabetes, obesity & metabolism, Chuang Shih-Ming et al.)
A case report links GLP-1 receptor activity to prolactin changes
Researchers flagged a puzzling hormone shift in a patient using a GLP-1 peptide. Here is what the case report found and what questions it raises.
Source: Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis. (Case reports in medicine, Guimarães Gabriela N F et al.)
A phase 2 trial tests a GLP-1 peptide after brain bleeds
Can a weekly injectable peptide already known for metabolic research do anything useful after a brain bleed? A phase 2 trial across three Chinese medical centers is designed to find out.
Source: GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial (NCT NCT07613437, status: NOT_YET_RECRUITING)
GLP-1 peptides studied in liver transplant patients with weight gain
What happens when researchers track GLP-1 peptide use in liver transplant patients? A new multicenter study offers some of the clearest data yet.
Source: Safety, tolerability and efficacy of GLP-1 receptor agonists (GLP-1 RA) in the management of post-liver transplant weight gain: A multicenter, observational study. (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, Khan Mohammad Qasim et al.)
How GLP-1 receptor agonists affect the body beyond weight
Researchers reviewed dozens of trials to ask whether obesity medications do anything useful beyond shrinking fat mass. The answer, the literature suggests, is yes, and the list is long.
Source: Beyond weight loss: multisystem benefits of obesity medications. (The lancet. Diabetes & endocrinology, Savas Mesut et al.)
GLP-1 peptides reduce fat but may also trim lean mass
Researchers compared 17 GLP-1 drug variations across 43 trials. Fat dropped, but lean mass took a hit at higher doses. Here is what the data showed.
Source: Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. (Diabetes, obesity & metabolism, Wachiraphansakul Nuttaya et al.)
How diabetes and two drug classes reshape kidney gene activity
A 2026 study sequenced the entire gene activity of a tiny kidney segment to understand how diabetes and two classes of metabolic drugs change cellular behavior at the molecular level.
Source: Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism. (American journal of physiology. Renal physiology, Kim Young Chul et al.)
How GLP-1 receptor research connects diabetes and stroke risk
Researchers reviewing major cardiovascular trials ask whether a class of incretin-based peptides does more than lower blood sugar, and what the current evidence actually supports.
Source: Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists. (Pharmaceutics, Paceana Maria-Alexandra et al.)
Silk nanoparticles could make oral peptide delivery more practical
Most peptide drugs have to be injected because the gut destroys them. A new nanoparticle platform made from silk may change that equation.
Source: Functional Performance of Silk Nanoparticles for Oral Drug Delivery. (ACS applied materials & interfaces, Jacobus Charlotte et al.)
How a GLP-1 peptide may protect bone cells in diabetic gum disease
Researchers found that a long-acting GLP-1 peptide blocked a damaging iron-driven cell death pathway in bone cells stressed by a diabetic environment. Here is what the study measured.
Source: Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway. (Drug design, development and therapy, Zhang Zhen et al.)
GLP-1 receptor peptides and what researchers found in eye tissue
GLP-1 receptor peptides are studied mostly for blood sugar and weight. A new review asks what happens to the eyes, and the answer turns out to be complicated.
Source: Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. (Vision (Basel, Switzerland), Lixi Filippo et al.)
How BPC-157 was studied in muscle tissue after blood flow injury
When blood flow is cut off and then restored, the returning oxygen can paradoxically destroy tissue. Researchers tested whether BPC-157 could interrupt that process.
Source: Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. (Scientific reports, Yıldırım Alperen Kutay et al.)
Why BPC-157 research still faces major development hurdles
BPC-157 has a rich preclinical record, yet no approved formulation exists. A 2026 review explains exactly what pharmaceutical science still needs to answer.
Source: BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. (Pharmaceutics, Mateescu Diana-Maria et al.)
How scientists read the fingerprints of complex peptides
Why is identifying a cyclic or chemically modified peptide so hard, and what did researchers build to fix that problem?
Source: Structure-aware fragment assignment for interpreting tandem mass spectrometry of modified and cyclic peptides. (The Analyst, Erckes V et al.)
How a GLP-1 peptide may protect the brain after diabetic hemorrhage
Researchers found that a GLP-1 receptor agonist blocked a damaging immune cascade inside brain blood vessels after hemorrhage, pointing to a molecular path that had not been described before.
Source: Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-β overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage. (Journal of neuroinflammation, Wang Yan et al.)
New computational tools map how proteins misbehave at scale
Why do some proteins clump into harmful fibers while others form temporary liquid compartments? A new computational framework gives researchers a fast way to find out across the whole human proteome.
Source: amyloid-predict and LLPS-predict: Predicting phase separation propensities in the intrinsically disordered proteome. (Proceedings of the National Academy of Sciences of the United States of America, Lobo Samuel et al.)
GLP-1 research in schizophrenia spectrum disorders explained
People with schizophrenia spectrum disorders face unusually high rates of obesity. Researchers pooled trial data to see whether a GLP-1 peptide could shift that picture.
Source: The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. (BJPsych open, Trott Mike et al.)
What a large meta-analysis found about cagrilintide and weight
Researchers pooled data from thousands of participants to see how a long-acting amylin analogue stacks up against placebo for weight and cardiometabolic outcomes.
Source: Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. (Journal of diabetes and metabolic disorders, Rao Hammad et al.)
A large study maps health outcomes tied to GLP-1 diabetes drugs
What happens across hundreds of health measures after someone with type 2 diabetes is prescribed a GLP-1 receptor agonist? A large real-world study tried to find out.
Source: Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us. (Nature communications, Salvatore Maxwell et al.)
A new trial asks whether a metabolic peptide can help people quit smoking
Researchers at four major universities want to know whether tirzepatide, a peptide that targets two metabolic hormones at once, might make it easier for people with overweight or obesity to stop smoki
Source: Multi-Site Trial of Tirzepatide for Smoking Cessation (NCT NCT07602699, status: RECRUITING)
Why combining two gut hormones may outperform one alone
Researchers are asking why pairing two gut-hormone pathways produces stronger metabolic results than targeting either one on its own. A major review unpacks the science.
Source: The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms. (Annual review of nutrition, Davies Iona et al.)
How weight loss therapies can affect bone and muscle health
Weight loss sounds straightforwardly good, but researchers are asking whether it also quietly weakens bone and muscle, and what the evidence actually shows.
Source: Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes (Endocrine News)
Combining a GLP-1 peptide with sleeve surgery: what researchers found
Can a short course of a GLP-1 peptide after bariatric surgery push outcomes further? A 2026 prospective study measured exactly that over twelve months.
Source: Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study. (Obesity surgery, Huang Yi Shan et al.)
What a clinical trial found when researchers infused GIP for six weeks
GIP is one half of a celebrated hormone pair. A rigorous trial just tested it head-on for glucose control, and the results were more complicated than expected.
Source: Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. (The lancet. Diabetes & endocrinology, Helsted Mads M et al.)
When bariatric surgery falls short, a peptide trial offers new data
Bariatric surgery does not always produce the expected weight loss. A 68-week trial now gives researchers hard numbers on whether a GLP-1 receptor agonist peptide can close that gap.
Source: Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. (Nature medicine, Stanley Chloe et al.)
GLP-1 peptides and heart failure: what the research shows
Researchers reviewed whether GLP-1 receptor agonist peptides, first studied in diabetes, might change outcomes for people living with heart failure.
Source: [Glucagon-like peptide-1 agonists and heart failure]. (Revue medicale suisse, Soborun Nisha et al.)
How weight loss affects the brain, according to researchers
Can losing a substantial amount of weight measurably change how the brain uses oxygen and processes information? A forthcoming trial is designed to find out.
Source: Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss (NCT NCT07592546, status: NOT_YET_RECRUITING)
How GLP-1 receptor agonists may affect fatty liver disease
Researchers reviewed dozens of studies to explain why a class of metabolic peptides seems to help with fatty liver disease, and the answer involves at least four overlapping biological networks.
Source: GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review. (Journal of endocrinological investigation, Wang Xuejia et al.)
GLP-1 peptides and unusual skin sensations: what researchers found
Social media reports of burning skin during GLP-1 peptide use prompted a formal database review. Researchers found a real signal, and the findings are worth understanding.
Source: Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. (European journal of clinical pharmacology, Laroche Marie-Laure et al.)
A new trial is testing a GLP-1 peptide for cocaine use disorder
No FDA-approved drug exists for cocaine use disorder. Researchers are now testing whether a peptide that acts on the brain's reward system could change that picture.
Source: Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. (BMJ open, Yammine Luba et al.)
What happens to the body when incretin therapy stops
Millions of people stop incretin-based medications within a year. A major review asks what that stopping actually does to the heart, blood sugar, and body weight.
Source: Causes and consequences of discontinuation of GLP1RAs or tirzepatide. (Nature reviews. Endocrinology, Ceriello Antonio et al.)
A GLP-1 peptide slowed biological aging clocks in a randomized trial
Could a peptide that targets metabolic receptors also slow how fast the body ages at a molecular level? A randomized trial measured exactly that.
Source: Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. (Nature communications, Corley Michael J et al.)
A dual GIP/GLP-1 peptide reduced protein in urine for Fabry patients
Could a metabolic peptide do kidney-protective work in a rare genetic disease? A recent abstract tested exactly that idea in 15 patients.
Source: DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Riccio Eleonora et al.)
What a major review found about peptides and sports recovery
Peptides are being used in sports medicine faster than research can keep up. A 2026 review mapped exactly where the evidence stands and where it falls short.
Source: Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. (JBJS reviews, Villegas Meza Alan D et al.)
Library guides
Research Peptides 101: A Plain-English Primer
What peptides are, why purity matters, and how to read a Certificate of Analysis without a chemistry degree.
GLP-1 Receptor Research: Single, Dual, and Triple Agonists
From single-target GLP-1 agonists to triple agonists hitting GLP-1, GIP, and glucagon. Mechanism, generations, and what the next wave of research looks at.
BPC-157: Mechanism of Action and Research Overview
A fragment of a gastric protein became one of the most-studied peptides in connective-tissue research. Here is what the literature actually shows.
Growth Hormone Peptides: Secretagogues, Releasing Hormones, and IGF-1
Native growth hormone has a half-life of about 17 minutes. Here is how the peptides that prompt it, mimic it, and amplify it actually work.
Recovery and Repair Peptides: BPC-157, TB-500, GHK-Cu, and KPV
Four peptides, four different mechanisms, one shared research focus: getting damaged tissue to heal faster than it would on its own.
NAD+, MOTS-c, and Mitochondrial Research Peptides
Mitochondria have their own genome and encode their own peptides. Here is what the research on NAD+ and MOTS-c suggests about cellular energy metabolism.
Cognitive Peptides: Semax, Selank, Pinealon, and DSIP
Russian research labs spent four decades studying short peptides for cognitive and mood endpoints. Here is what the literature on Semax, Selank, Pinealon, and DSIP actually shows.
How to Read a Certificate of Analysis
A COA is the lab report that backs up the label. Here is what each section means and the three things that should make you stop and ask questions.
Bacteriostatic Water and Reconstitution: A Practical Primer
Sterile water and bacteriostatic water are not the same thing. Here is the difference, and the simple math that turns a 10mg vial into a known concentration.
Retatrutide Research Overview: The Triple Agonist
Retatrutide is the most-studied triple agonist on the metabolic receptor axis. Here is the mechanism, what the studies looked at, and the open questions.
Tesamorelin Research Overview: A GHRH Analog for Visceral Fat
Tesamorelin is one of the few growth-hormone-axis peptides with a clean FDA-approval history. Here is the mechanism and what the published data looked at.
PT-141 Research: A Centrally Acting Melanocortin Agonist
PT-141 acts on melanocortin receptors in the central nervous system, not on the vasculature. Here is what the receptor literature suggests about the mechanism.
Thymosin Alpha-1 Immune Research Overview
Thymosin alpha-1 has been studied in immune research for more than four decades. Here is the mechanism, the data, and where it fits.
Melanotan 2 Research Overview
Melanotan 2 is a melanocortin agonist originally developed in academic skin-cancer research. Here is the mechanism and what the literature shows.
Stack Design Principles: How Research Peptide Stacks Are Built
Stacks are not just a marketing concept. Here is how researchers think about combining peptides without doubling up on the same mechanism.
BPC-157 vs TB-500: Two Recovery Peptides, Two Mechanisms
BPC-157 and TB-500 are the two most-cited recovery peptides in the research literature. They have different mechanisms, which is why they are often studied together rather than against each other.
Sermorelin vs CJC-1295 + Ipamorelin: Two Approaches to the GH Pulse
Sermorelin is one molecule, one receptor. CJC-1295 + ipamorelin is two molecules and two receptors. Here is what that means for the GH pulse they produce.
Single, Dual, and Triple Incretin Agonists: The Generation Comparison
Single, dual, triple. Three generations of incretin agonists, each adding one more receptor. Here is the side-by-side comparison of what each generation actually changes.
Want a stack picked for your goals?
The six-step assessment maps your goals, experience, and contraindications to a curated peptide stack. Free, no signup, two minutes.
Take the Assessment